Surzebiclimab

舒泽利单抗

Report date: 2026/04/03 20:03:44

Base Information

Drug NameSurzebiclimab
Drug Alias NameBGB-A425
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitors
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdBeOne Medicines Ltd
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A